Möchten Sie immer auf dem neuesten Stand bleiben?

NEW YORK, March 30, 2026, March 30, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP encourages investors who suffered losses in REGENXBIO, Inc. (NASDAQ: RGNX) to contact the firm. Those who...

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) of a class action securities lawsuit. CLASS...

- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p<0.0001) and 49.3% in CVM (p<0.0001)  - Acoramidis mitigated the rise in NT-proBNP...

AquaBurn 2026 brown fat thermogenic formula: ingredient research context, product disclosures, and supplement vs. prescription distinctions.

LOS ANGELES, March 30, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed...

LOS ANGELES, March 30, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following...

New class action for uniQure N.V. (QURE) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/13/2026.

New class action for Atara (ATRA) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 5/22/2026.

New class action for Inovio (INO) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 4/7/2026.

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

INO Investors Have Opportunity to Lead Inovio Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

Gilroy, CA, March 30, 2026 (GLOBE NEWSWIRE) -- Families in Gilroy can skip the pranks and lose the lice this spring. Lice Clinics of America – Gilroy is hosting a one-day “Great Lice Egg Hunt” event...

HairSmart redefines genetic hair loss with a drug-free protocol combining natural DHT blockers and medical-grade laser technology for safer regrowth.

Completed strategic acquisition of dual-targeting CAR-T assets from Factor Bioscience Inc. Named Matt Angel, Ph.D., Chief Executive Officer & President Announced positive interim data from the...

LOS ANGELES, March 30, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Corcept Therapeutics Incorporated, (“Corcept” or the "Company") (NASDAQ: CORT) investors of a class action on behalf of...

– Full enrollment of BLA-enabling trial complete, per prior guidance –– Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch –– Onboarded Chief Medical...

ARLINGTON, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ: KALA) (“Kala” or the “Company”) today announced the initial commercial deployment of the Bionic Intelligence Research...

New York, March 30, 2026 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates today’s announcement that the U.S. Food and Drug Administration (FDA) has approved a High Dose...

Company completed treatment in four additional participate at its Israel clinical site Vancouver, Canada, March 30, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or...

NOVATO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New...

Austin, United States, March 30, 2026 (GLOBE NEWSWIRE) -- Chemotherapy Market Size & Growth Analysis: According to SNS Insider, the Chemotherapy Market was valued at $10.14 billion in 2025,...

Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data  In vitro analysis of the SeaStar Medical SCD...

Reports Significant Revenue Growth and Gross Margin Expansion in 2025 COMMACK, NY, March 30, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for...

UroGen announces that the pivotal ENVISION 24 mo. Duration of Response date has been published online in The Journal of Urology.

Data showed 50% or more of patients reporting >50% improvement in key pain and function scales  No adverse events related to dose-limiting toxicities associated with hypoxic-cultured mesenchymal...

VANCOUVER, British Columbia, March 30, 2026 (GLOBE NEWSWIRE) -- Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company”), a food-tech innovation company dedicated to reducing...

Tevas Biosimilar PONLIMSI™ ist nun von der FDA für alle Indikationen des Referenzprodukts Prolia® (Denosumab) zur Behandlung verschiedener schwerer Knochenerkrankungen zugelassen.Tevas vorgeschlagener...

Le médicament biosimilaire de Teva, PONLIMSI™, est désormais approuvé par la FDA pour toutes les indications du produit de référence, Prolia® (dénosumab), dans le cadre du traitement de diverses...

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia® (denosumab), to treat a variety of debilitating bone conditions.Teva’s proposed biosimilar...

MediPharm Labs, today announced its financial results for the full year and three months ended December 31st, 2025.

With Priority Review designation, FDA set a Sept. 27 PDUFA date for approval decisionLirafugratinib achieved a 46.5% ORR, in CCA patients with FGFR2 fusion and rearrangement Fort Lee, N.J., March ...

Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) --  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today...

- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418’s rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically...

PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...

Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript...

The approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA...

Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer’s disease Additional data submitted to the U.S. FDA with the...

MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...

Appili Presentation Highlights Recent Collaborations and Funding Milestones Appili Executives to Conduct In-Person Meetings and in Washington, D.C. to Identify New Funding Opportunities HALIFAX,...

Oxylanthanum carbonate (OLC) New Drug Application (NDA) resubmission under review by U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June...

PMGC Holdings Inc. [NASDAQ: ELAB] Reports 2025 Annual Results and Files Form 10-K, Company Expands Asset Base to $13.8M, a 43% Increase from 2024

Reaffirms guidance to resubmit the Anaphylm NDA in Q3 2026Received clarifying feedback from the FDA on pharmacokinetic (PK) and human factor (HF) study designsFinal FDA meeting minutes expected by...

Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time ...

– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing...

Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 ...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "PD-1 Resistant Head and Neck Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering. The PD-1 resistant head and neck...

- Written FDA recommendations include a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for schizophrenia – - Current data package...

U.S. FDA Fast Track designation granted to ZW191, an antibody-drug conjugate targeting folate receptor-α (FRα), for the treatment of patients with advanced or metastatic platinum-resistant ovarian...

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Carcinoid Tumor Market Report 2026" has been added to ResearchAndMarkets.com's offering.The global carcinoid tumor market is rapidly expanding, with...